285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors

• Marcus Butler,
• David Hong,
• Ryan Sullivan,
• Matthew Frigault,
• Sarah Boross-Harmer,
• Ecaterina Dumbrava,
• Jean-Marc Navenot,
• Svetlana Fayngerts,
• Jane Bai,
• Elliot Norry,
• Paula Fracasso,
• Russell Pachynski,
• Partow Kebriaei,
• Amy Sauer,
• Francine Brophy

Affiliations

Marcus Butler

2Princess Margaret Cancer Centre, Toronto, Ontario, Canada

David Hong

1MD Anderson Cancer Center, Houston, TX, USA

Ryan Sullivan

3Massachusetts General Hospital, Boston, MA, USA

Matthew Frigault

5Massachusetts General Hospital, Somerville, MA, USA

Sarah Boross-Harmer

2Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Ecaterina Dumbrava

1MD Anderson Cancer Center, Houston, TX, USA

Jean-Marc Navenot

6Adaptimmune, Philadelphia, PA, USA

Svetlana Fayngerts

6Adaptimmune, Philadelphia, PA, USA

Jane Bai

6Adaptimmune, Philadelphia, PA, USA

Elliot Norry

6Adaptimmune, Philadelphia, PA, USA

Paula Fracasso

6Adaptimmune, Philadelphia, PA, USA

Russell Pachynski

3Washington University School of Medicine, St Louis, MO, USA

Partow Kebriaei

1MD Anderson Cancer Center, Houston, TX, USA

Amy Sauer

6Adaptimmune, Philadelphia, PA, USA

Francine Brophy

6Adaptimmune, Philadelphia, PA, USA